Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Neuroimage Clin ; 38: 103401, 2023.
Article in English | MEDLINE | ID: mdl-37060626

ABSTRACT

BACKGROUND: Deficits in cognition like working memory (WM) are highly prevalent symptoms related to major depressive disorder (MDD). Neuroimaging studies have described frontoparietal abnormalities in patients with MDD as a basis for these deficits. Based on research in healthy adults, it is hypothesized that increased physical fitness might be a protective factor for these deficits in MDD. However, the relationship between physical fitness and WM-related neural activity and performance has not been tested in MDD, to date. Understanding these associations could inform the development of physical exercise interventions in MDD. METHODS: Within a larger project, 111 (53female) MDD outpatients and 56 (34female) healthy controls performed an n-back task (0-, 1-, 2-, 3-back) during functional Magnetic Resonance Imaging. Physical fitness from a graded exercise test on a cycle ergometer was performed by 106 MDD patients. RESULTS: Patients showed reduced performance particularly at high loads of the n-back WM task and prolonged reaction times at all n-back loads. A whole-brain interaction analysis of group by WM load revealed reduced neural activity in six frontoparietal clusters at medium and high WM loads in MDD patients compared to healthy controls. Analysis of covariance within the MDD sample showed that physical fitness was associated with neural activity in right and left superior parietal lobules. Externally defined Regions of Interest confirmed this analysis. CONCLUSIONS: Results indicate frontoparietal hypoactivity in MDD at high demands, arguing for decreased WM capacity. We demonstrate a parietal fitness correlate which could be used to guide future research on effects of exercise on cognitive functioning in MDD.


Subject(s)
Depressive Disorder, Major , Memory, Short-Term , Adult , Humans , Depressive Disorder, Major/diagnostic imaging , Brain Mapping , Cognition , Magnetic Resonance Imaging , Physical Fitness
2.
BMC Health Serv Res ; 21(1): 593, 2021 Jun 21.
Article in English | MEDLINE | ID: mdl-34154599

ABSTRACT

BACKGROUND: Depression is one of the key factors contributing to difficulties in one's ability to work, and serves as one of the major reasons why employees apply for psychotherapy and receive insurance subsidization of treatments. Hence, an increasing and growing number of studies rely on workability assessment scales as their primary outcome measure. The Work and Social Assessment Scale (WSAS) has been documented as one of the most psychometrically reliable and valid tools especially developed to assess workability and social functioning in patients with mental health problems. Yet, the application of the WSAS in Germany has been limited due to the paucity of a valid questionnaire in the German language. The objective of the present study was to translate the WSAS, as a brief and easy administrable tool into German and test its psychometric properties in a sample of adults with depression. METHODS: Two hundred seventy-seven patients (M = 48.3 years, SD = 11.1) with mild to moderately severe depression were recruited. A multistep translation from English into the German language was performed and the factorial validity, criterion validity, convergent validity, discriminant validity, internal consistency, and floor and ceiling effects were examined. RESULTS: The confirmatory factor analysis results confirmed the one-factor structure of the WSAS. Significant correlations with the WHODAS 2-0 questionnaire, a measure of functionality, demonstrated good convergent validity. Significant correlations with depression and quality of life demonstrated good criterion validity. The WSAS also demonstrated strong internal consistency (α = .89), and the absence of floor and ceiling effects indicated good sensitivity of the instrument. CONCLUSIONS: The results of the present study demonstrated that the German version of the WSAS has good psychometric properties comparable to other international versions of this scale. The findings recommend a global assessment of psychosocial functioning with the sum score of the WSAS. TRIAL REGISTRATION: ISRCTN identifier: ISRCTN28972230 . Date of registration June 26th 2018.


Subject(s)
Language , Social Adjustment , Adult , Germany , Humans , Psychometrics , Quality of Life , Reproducibility of Results , Surveys and Questionnaires
3.
Curr Med Res Opin ; 22 Suppl 1: S19-22, 2006.
Article in English | MEDLINE | ID: mdl-16882366

ABSTRACT

The addition of recombinant human bone morphogenetic protein (rhBMP-2) to the standard of care, consisting of soft tissue management and intramedullary nailing, in the BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) study led to a significantly better outcome for the patient. Reductions in fracture healing time, secondary interventions for delayed fracture healing and infection rates were observed with 1.50 mg/mL rhBMP-2 compared with the standard of care alone. In Germany the approximate cost of applying one dose of recombinant human bone morphogenetic protein-2 (rhBMP-2) to an open tibial fracture is euro2970. The current German-Diagnosis-Related Group reimbursement system provides one flat rate per hospital stay or treatment case, and does not take into account the costs of rhBMP-2 application. Therefore there is no reimbursement for the price of rhBMP-2 for hospitals by health insurance companies. However, the above mentioned improvements in medical outcome could lead to important savings for health care systems, particularly for health insurance companies. A sound economic model to assess the cost-effectiveness and budget impact of rhBMP-2 is required. Using medical data from the BESTT study the differences in fracture healing time, in reduction of secondary interventions for fracture healing and infection treatment can be transferred into economic savings. It is anticipated that the overall savings that can be achieved by rhBMP-2 treatment in open tibia fractures, offset the upfront price of rhBMP-2 and lead to net savings for health insurance companies.


Subject(s)
Bone Morphogenetic Proteins/economics , Bone Morphogenetic Proteins/therapeutic use , Recombinant Proteins/economics , Recombinant Proteins/therapeutic use , Tibial Fractures/drug therapy , Tibial Fractures/economics , Transforming Growth Factor beta/economics , Transforming Growth Factor beta/therapeutic use , Bone Morphogenetic Protein 2 , Cost-Benefit Analysis , Drug Costs , Europe , Germany , Humans
5.
Dtsch Tierarztl Wochenschr ; 106(8): 362-3, 1999 Aug.
Article in German | MEDLINE | ID: mdl-10488643

ABSTRACT

A significant economic evidence of zoonotic disease can be observed with costs of illness in the range of billions of DM. The lack of competitive structures in the German health care system calls for the use of economic evaluations. By the cautions use of these measures possibilities for rationalizing can be discovered and utilized.


Subject(s)
Communicable Disease Control/economics , Zoonoses , Animals , Costs and Cost Analysis , Germany , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...